These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 16722544)
1. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Zimmermann M; Zouhair A; Azria D; Ozsahin M Radiat Oncol; 2006 May; 1():11. PubMed ID: 16722544 [TBL] [Abstract][Full Text] [Related]
3. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Burtness B Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785 [TBL] [Abstract][Full Text] [Related]
4. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Herbst RS; Hong WK Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Rubin Grandis J; Chakraborty A; Melhem MF; Zeng Q; Tweardy DJ Oncogene; 1997 Jul; 15(4):409-16. PubMed ID: 9242377 [TBL] [Abstract][Full Text] [Related]
6. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Vokes EE; Chu E Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979 [TBL] [Abstract][Full Text] [Related]
7. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Karamouzis MV; Grandis JR; Argiris A JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492 [TBL] [Abstract][Full Text] [Related]
8. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines. Oshima G; Wennerberg J; Yamatodani T; Kjellén E; Mineta H; Johnsson A; Ekblad L J Cancer Res Clin Oncol; 2012 Mar; 138(3):491-9. PubMed ID: 22193422 [TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134 [TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor directed therapy in head and neck cancer. Choong NW; Cohen EE Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530 [TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin. Baumeister P; Reiter M; Schwenk-Zieger S; Harréus U Chemotherapy; 2010; 56(4):268-74. PubMed ID: 20693797 [TBL] [Abstract][Full Text] [Related]
12. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Kim S; Grandis JR; Rinaldo A; Takes RP; Ferlito A Head Neck; 2008 May; 30(5):667-74. PubMed ID: 18383530 [TBL] [Abstract][Full Text] [Related]
13. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342 [TBL] [Abstract][Full Text] [Related]
14. The epidermal growth factor receptor as a target for colorectal cancer therapy. Lockhart AC; Berlin JD Semin Oncol; 2005 Feb; 32(1):52-60. PubMed ID: 15726506 [TBL] [Abstract][Full Text] [Related]
15. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870 [TBL] [Abstract][Full Text] [Related]
16. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991 [TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Ang KK; Andratschke NH; Milas L Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):959-65. PubMed ID: 14967456 [TBL] [Abstract][Full Text] [Related]
18. The role of inhibitors of the epidermal growth factor in management of head and neck cancer. Brockstein B; Lacouture M; Agulnik M J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458 [TBL] [Abstract][Full Text] [Related]
19. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711 [TBL] [Abstract][Full Text] [Related]
20. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer. Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A J BUON; 2009; 14(1):19-25. PubMed ID: 19373942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]